ArticleFrontiers in immunology2023

Immunity following SARS-CoV-2 vaccination in autoimmune neurological disorders treated with rituximab or ocrelizumab.

Petra Nytrova et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.